Mineral and bone disorder in Chinese dialysis patients: a multicenter study
详细信息 查看全文
- 作者：Xianglei Kong (1) (26)
Luxia Zhang (1)
Ling Zhang (2)
Nan Chen (3)
Yong Gu (4)
Xueqing Yu (5)
Wenhu Liu (6)
Jianghua Chen (7)
Liren Peng (8)
Weijie Yuan (9)
Hua Wu (10)
Wei Chen (11)
Minhua Fan (12)
Liqun He (13)
Feng Ding (14)
Xiangmei Chen (15)
Zuying Xiong (16)
Jinyuan Zhang (17)
Qiang Jia (18)
Wei Shi (19)
Changying Xing (20)
Xiaoling Tang (21)
Fanfan Hou (22)
Guiyang Shu (23)
Changlin Mei (24)
Li Wang (25)
Dongmei Xu (26)
Zhaohui Ni (27)
Li Zuo (1)
Mei Wang (1) (28) (29)
Haiyan Wang (1) - 关键词：End stage renal disease ; Mineral and bone disorder ; Epidemiology
- 刊名：BMC Nephrology
- 出版年：2012
- 出版时间：December 2012
- 年：2012
- 卷：13
- 期：1
- 全文大小：261KB
- 参考文献：1. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. / J Am Soc Nephrol 2004,15(8):2208-218. CrossRef
2. Hruska KA, Saab G, Mathew S, Lund R: Renal osteodystrophy, phosphate homeostasis, and vascular calcification. / Semin Dial 2007,20(4):309-15. CrossRef
3. Palmer SC, Hayen A, Macaskill P, / et al.: Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. / JAMA 2011,305(11):1119-127. CrossRef
4. Levin A, Bakris GL, Molitch M, / et al.: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. / Kidney Int 2007,71(1):31-8. CrossRef
5. Gutierrez O, Isakova T, Rhee E, / et al.: Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. / J Am Soc Nephrol 2005,16(7):2205-215. CrossRef
6. Wald R, Tentori F, Tighiouart H, Zager PG, Miskulin DC: Impact of the Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guidelines for Bone Metabolism and Disease in a large dialysis network. / Am J Kidney Dis 2007,49(2):257-66. CrossRef
7. Tentori F: Mineral and bone disorder and outcomes in hemodialysis patients: results from the DOPPS. / Semin Dial 2010,23(1):10-4. CrossRef
8. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease: / Am J Kidney Dis. 2003,42(4 Suppl 3):S1-S201.
9. Dialysis Outcomes and Practice Patterns Study: / DOPPS annual report. 2010. http://www.dopps.org/annualreport/index.htm
10. Kalantar-Zadeh K, Kuwae N, Regidor DL, / et al.: Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. / Kidney Int 2006,70(4):771-80. CrossRef
11. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. / Am J Kidney Dis 1998,31(4):607-17. CrossRef
12. Schwarz S, Trivedi BK, Kalantar-Zadeh K, Kovesdy CP: Association of disorders in mineral metabolism with progression of chronic kidney disease. / Clin J Am Soc Nephrol 2006,1(4):825-31. CrossRef
13. Kovesdy CP, Kalantar-Zadeh K: Serum phosphorus and the risk of progression of chronic kidney disease. / Nephrol Dial Transplant 2007,22(12):3679-680. CrossRef
14. Zhao L, Stamler J, Yan LL, / et al.: Blood pressure differences between northern and southern Chinese: role of dietary factors: the International Study on Macronutrients and Blood Pressure. / Hypertension 2004,43(6):1332-337. CrossRef
15. Walsh M, Manns BJ, Klarenbach S, Tonelli M, Hemmelgarn B, Culleton B: The effects of nocturnal compared with conventional hemodialysis on mineral metabolism: A randomized-controlled trial. / Hemodial Int 2010,14(2):174-81. CrossRef
16. Pierratos A, Ouwendyk M, Francoeur R, / et al.: Nocturnal hemodialysis: three-year experience. / J Am Soc Nephrol 1998,9(5):859-68.
17. Ayus JC, Mizani MR, Achinger SG, Thadhani R, Go AS, Lee S: Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. / J Am Soc Nephrol 2005,16(9):2778-788. CrossRef
18. Maduell F, Navarro V, Torregrosa E, / et al.: Change from three times a week on-line hemodiafiltration to short daily on-line hemodiafiltration. / Kidney Int 2003,64(1):305-13. CrossRef
19. Tonelli M, Wang W, Hemmelgarn B, Lloyd A, Manns B: Phosphate removal with several thrice-weekly dialysis methods in overweight hemodialysis patients. / Am J Kidney Dis 2009,54(6):1108-115. CrossRef
20. Penne EL, van der Weerd NC, van den Dorpel MA, / et al.: Short-term effects of online hemodiafiltration on phosphate control: a result from the randomized controlled Convective Transport Study (CONTRAST). / Am J Kidney Dis 2010,55(1):77-7. CrossRef
21. Melamed ML, Eustace JA, Plantinga L, / et al.: Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. / Kidney Int 2006,70(2):351-57. CrossRef
22. Wald R, Sarnak MJ, Tighiouart H, / et al.: Disordered mineral metabolism in hemodialysis patients: an analysis of cumulative effects in the Hemodialysis (HEMO) Study. / Am J Kidney Dis 2008,52(3):531-40. CrossRef
23. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): / Kidney Int Suppl. 2009,76(113):S1-S130.
24. Soroka SD, Beard KM, Mendelssohn DC, Cournoyer SH, Da Roza GA, Geary DF: Mineral metabolism management in Canadian peritoneal dialysis patients. / Clin Nephrol 2011,75(5):410-15.
25. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2369/13/116/prepub - 作者单位：Xianglei Kong (1) (26)
Luxia Zhang (1)
Ling Zhang (2)
Nan Chen (3)
Yong Gu (4)
Xueqing Yu (5)
Wenhu Liu (6)
Jianghua Chen (7)
Liren Peng (8)
Weijie Yuan (9)
Hua Wu (10)
Wei Chen (11)
Minhua Fan (12)
Liqun He (13)
Feng Ding (14)
Xiangmei Chen (15)
Zuying Xiong (16)
Jinyuan Zhang (17)
Qiang Jia (18)
Wei Shi (19)
Changying Xing (20)
Xiaoling Tang (21)
Fanfan Hou (22)
Guiyang Shu (23)
Changlin Mei (24)
Li Wang (25)
Dongmei Xu (26)
Zhaohui Ni (27)
Li Zuo (1)
Mei Wang (1) (28) (29)
Haiyan Wang (1)
1. Renal Division, Department of Medicine, Peking University First Hospital; Peking University Institute of Nephrology; Key Laboratory of Renal Disease, Ministry of Health of China, Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing, China
26. Department of Nephrology, Qianfoshan Hospital, Shandong University, Jinan, China
2. Department of Nephrology, China-Japan Friendship Hospital, Beijing, China
3. Department of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China
4. Renal Division, Xinhua Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China
5. Department of Nephrology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
6. Department of Nephrology, Beijing Friendship Hospital, Capital Medical University, Beijing, China
7. Kidney Diseases Center, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
8. Department of Nephrology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
9. Department of Nephrology, Shanghai First People s Hospital, Shanghai Jiaotong University, Shanghai, China
10. Department of Nephrology, Beijing Hospital, Beijing, China
11. Department of Nephrology, Xijing Hospital, Fourth Military Medical University, Xi’an, China
12. Department of Nephrology, Peking University Third Hospital, Beijing, China
13. Department of Nephrology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China
14. Department of Nephrology, Huashan Hospital, Fudan University, Shanghai, China
15. Department of Nephrology, The General Hospital of the People’s Liberation Army, Beijing, China
16. Renal Division, Hospital Peking of Shenzhen, Shenzhen, China
17. Department of Nephrology, The 455th Hospital of PLA, Shanghai, China
18. Department of Nephrology, Xuanwu Hospital, Capital Medical University, Beijing, China
19. Department of Nephrology, Guangdong General Hospital, Guangzhou, China
20. Renal Division, Jiangsu Provincial Hospital, Nanjing, China
21. Department of internal medicine, Shantou Central Hospital, Shantou, China
22. Department of Nephrology, Nanfang Hospital, The Southern Medical University, Guangzhou, China
23. Department of Nephrology, Fujian Provincial Hospital, Fuzhou, China
24. Department of Nephrology, Changzheng Hospital, Second Military Medical University, Shanghai, China
25. Department of Nephrology, Sichuan Provincial People-s Hospital, Chengdu, China
27. Renal Division, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
28. Department of Nephrology, Peking University People’s Hospital, Beijing, China
29. Institute of Nephrology and Division of Nephrology, and Key Laboratory of Ministry of Health, Peking University First Hospital, 8 Xishiku Street, Xicheng District, Beijing, 100034, China
文摘
Background Mineral and bone disorder (MBD) in patients with chronic kidney disease is associated with increased morbidity and mortality. Studies regarding the status of MBD treatment in developing countries, especially in Chinese dialysis patients are extremely limited. Methods A cross-sectional study of 1711 haemodialysis (HD) patients and 363 peritoneal dialysis (PD) patients were enrolled. Parameters related to MBD, including serum phosphorus (P), calcium (Ca), intact parathyroid hormone (iPTH) were analyzed. The achievement of MBD targets was compared with the results from the Dialysis Outcomes and Practice Study (DOPPS) 3 and DOPPS 4. Factors associated with hyperphosphatemia were examined. Results Total 2074 dialysis patients from 28 hospitals were involved in this study. Only 38.5%, 39.6% and 26.6% of them met the Kidney Disease Outcomes Quality Initiative (K/DOQI) defined targets for serum P, Ca and iPTH levels. Serum P and Ca levels were statistically higher (P-lt;-.05) in the HD patients compared with those of PD patients, which was (6.3?±-.1) mg/dL vs (5.7?±-.0) mg/dL and (9.3?±-.1) mg/dL vs (9.2?±-.1) mg/dL, respectively. Serum iPTH level were statistically higher in the PD patients compared with those of HD patients (P--.03). The percentage of patients reached the K/DOQI targets for P (37.6% vs 49.8% vs 54.5%, P-lt;-.01), Ca (38.6% vs 50.4% vs 56.0%, P-lt;-.01) and iPTH (26.5% vs 31.4% vs 32.1%, P-lt;-.01) were lower among HD patients, compared with the data from DOPPS 3 and DOPPS 4. The percentage of patients with serum phosphorus level above 5.5 mg/dL was 57.4% in HD patients and 47.4% in PD patients. Age, dialysis patterns and region of residency were independently associated with hyperphosphatemia. Conclusions Status of MBD is sub-optimal among Chinese patients receiving dialysis. The issue of hyperphosphatemia is prominent and needs further attention.